Version 1
: Received: 13 January 2021 / Approved: 13 January 2021 / Online: 13 January 2021 (13:07:39 CET)
Version 2
: Received: 13 July 2021 / Approved: 28 July 2021 / Online: 28 July 2021 (10:30:09 CEST)
Schlickeiser, R.; Kröger, M. Reasonable Limiting of 7-Day Incidence per Hundred Thousand and Herd Immunization in Germany and Other Countries. COVID, 2021, 1, 130–136. https://doi.org/10.3390/covid1010012.
Schlickeiser, R.; Kröger, M. Reasonable Limiting of 7-Day Incidence per Hundred Thousand and Herd Immunization in Germany and Other Countries. COVID, 2021, 1, 130–136. https://doi.org/10.3390/covid1010012.
Schlickeiser, R.; Kröger, M. Reasonable Limiting of 7-Day Incidence per Hundred Thousand and Herd Immunization in Germany and Other Countries. COVID, 2021, 1, 130–136. https://doi.org/10.3390/covid1010012.
Schlickeiser, R.; Kröger, M. Reasonable Limiting of 7-Day Incidence per Hundred Thousand and Herd Immunization in Germany and Other Countries. COVID, 2021, 1, 130–136. https://doi.org/10.3390/covid1010012.
Abstract
Based on the hospital capacities, facts from the past experience with the Covid-19 virus and the dark number of infections D=10D_{10} a reasonable limiting value of 170/D_{10} for the monitored 7-day incidence per 100000 persons value (MSDIHT) in Germany is calculated. If the MSDIHT is held below this limiting value the German hospital system can cope with the number of new seriously infected persons without any triage decisions. A significant improvement to an almost complete testing of the population would lead to dramatic reduction of the current dark numer value to D_{10}=0.1 so that ten times higher MSDIHT values of 1700 are acceptable. Such a high limiting value would spare Germany from its currently imposed strict lockdown. The costs for such extensive and complete testing campaigns are highly justified as they are orders of magnitudes below the estimated economical costs of more than 3.6 billion Euros for each lockdown day.
Medicine and Pharmacology, Epidemiology and Infectious Diseases
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
